Cargando…
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras+) and 57 (35.8%) had mutations of the p53 (p53+). There were 95 cases (59.7%)...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222780/ https://www.ncbi.nlm.nih.gov/pubmed/9099959 |
_version_ | 1782149387239030784 |
---|---|
author | Fukuyama, Y. Mitsudomi, T. Sugio, K. Ishida, T. Akazawa, K. Sugimachi, K. |
author_facet | Fukuyama, Y. Mitsudomi, T. Sugio, K. Ishida, T. Akazawa, K. Sugimachi, K. |
author_sort | Fukuyama, Y. |
collection | PubMed |
description | We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras+) and 57 (35.8%) had mutations of the p53 (p53+). There were 95 cases (59.7%) with ras- p53-, seven cases (4.4%) with ras+/p53-, 53 cases (33.3%) with ras-/p53+ and four cases (2.5%) with ras+/p53+. The ras+ group had a worse prognosis than the ras group in all cases and in 107 early-stage cases (stage I-II, P<0.05). The p53+ group had a worse prognosis in 107 early-stage cases (P<0.01), but there was no statistically significant difference when 52 advanced-stage cases (stage III-IV) or all patients were considered. Both ras and p53 mutations were unfavourable prognostic factors in 94 cases with adenocarcinoma, but there was no statistical significance in 57 cases with squamous cell carcinoma. According to Cox's model, the pathological stage, ras mutation and p53 mutation were found to be independent prognostic factors. Our results suggest that ras and p53 mutations were independent unfavourable prognostic markers especially in the early stage of NSCLC or in adenocarcinoma. |
format | Text |
id | pubmed-2222780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22227802009-09-10 K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Fukuyama, Y. Mitsudomi, T. Sugio, K. Ishida, T. Akazawa, K. Sugimachi, K. Br J Cancer Research Article We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras+) and 57 (35.8%) had mutations of the p53 (p53+). There were 95 cases (59.7%) with ras- p53-, seven cases (4.4%) with ras+/p53-, 53 cases (33.3%) with ras-/p53+ and four cases (2.5%) with ras+/p53+. The ras+ group had a worse prognosis than the ras group in all cases and in 107 early-stage cases (stage I-II, P<0.05). The p53+ group had a worse prognosis in 107 early-stage cases (P<0.01), but there was no statistically significant difference when 52 advanced-stage cases (stage III-IV) or all patients were considered. Both ras and p53 mutations were unfavourable prognostic factors in 94 cases with adenocarcinoma, but there was no statistical significance in 57 cases with squamous cell carcinoma. According to Cox's model, the pathological stage, ras mutation and p53 mutation were found to be independent prognostic factors. Our results suggest that ras and p53 mutations were independent unfavourable prognostic markers especially in the early stage of NSCLC or in adenocarcinoma. Nature Publishing Group 1997 /pmc/articles/PMC2222780/ /pubmed/9099959 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Fukuyama, Y. Mitsudomi, T. Sugio, K. Ishida, T. Akazawa, K. Sugimachi, K. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
title | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
title_full | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
title_fullStr | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
title_full_unstemmed | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
title_short | K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
title_sort | k-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222780/ https://www.ncbi.nlm.nih.gov/pubmed/9099959 |
work_keys_str_mv | AT fukuyamay krasandp53mutationsareanindependentunfavourableprognosticindicatorinpatientswithnonsmallcelllungcancer AT mitsudomit krasandp53mutationsareanindependentunfavourableprognosticindicatorinpatientswithnonsmallcelllungcancer AT sugiok krasandp53mutationsareanindependentunfavourableprognosticindicatorinpatientswithnonsmallcelllungcancer AT ishidat krasandp53mutationsareanindependentunfavourableprognosticindicatorinpatientswithnonsmallcelllungcancer AT akazawak krasandp53mutationsareanindependentunfavourableprognosticindicatorinpatientswithnonsmallcelllungcancer AT sugimachik krasandp53mutationsareanindependentunfavourableprognosticindicatorinpatientswithnonsmallcelllungcancer |